Halia Therapeutics (Lehi, UT) receives the prestigious Novo Nordisk Golden Ticket, granting access to advanced research facilities and mentorship, accelerating the development of therapies for chronic inflammation and obesity-related diseases.
Lehi, Utah - March 11, 2025
Halia Therapeutics, a clinical-stage biopharmaceutical company based in Lehi, Utah, is developing novel therapies for chronic inflammation and obesity-related diseases. Today, the company announced it has been awarded the Novo Nordisk Golden Ticket.
The Novo Nordisk Golden Ticket – BioLabs European Award recognizes promising biotech companies developing transformational therapies in cardiometabolic and obesity-related diseases. The award grants Halia access to state-of-the-art laboratory infrastructure, research facilities, and direct engagement with Novo Nordisk’s scientific and business executives. It includes one lab bench, a dedicated desk, and a BioLabs membership for one year, with an option to apply the value toward private lab space. Additionally, it ensures priority admission to BioLabs Heidelberg or Paris, offering mentorship and networking opportunities to accelerate research and development.
"Receiving the Novo Nordisk Golden Ticket is a significant milestone for Halia Therapeutics," said David J. Bearss, Ph.D., CEO of Halia Therapeutics. "This award provides valuable resources to advance our research and validates our approach to tackling chronic inflammation and obesity-related diseases. With access to BioLabs' premier facilities and mentorship from Novo Nordisk, we are in a stronger position to move HT-6184 toward clinical development."
Halia's lead candidate, HT-6184, targets the NEK7/NLRP3 inflammasome pathway to modulate inflammation in obesity and metabolic disorders. Additionally, HT-4253, a LRRK2 inhibitor, is being evaluated for its potential in neuroinflammation-related diseases. By addressing the root causes of inflammation-driven conditions, Halia aims to provide innovative solutions for diseases with significant unmet medical needs, including obesity, Alzheimer’s disease, and lower-risk myelodysplastic syndromes (LR-MDS).
HT-6184 is a first-in-class NEK7/NLRP3 inflammasome inhibitor designed to target metaflammation—the chronic, low-grade inflammation associated with obesity, metabolic dysfunction, and related diseases. Preclinical studies have demonstrated that HT-6184 enhances the effects of GLP-1 receptor agonists, promoting weight loss while preserving lean mass and reducing inflammation. The company is preparing to initiate a Phase 2 clinical study in combination with Semaglutide in early 2025.
This recognition further strengthens Halia’s position in the European biotech ecosystem and provides a critical pathway for global expansion and strategic partnerships. By leveraging this opportunity, Halia is well-positioned to accelerate the development of its therapies and contribute to the advancement of treatments for inflammation-driven diseases.
For more information visit Halia's website at haliatx.com.